Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

Steven A. Rosenberg, James C. Yang, Douglas J. Schwartzentruber, Patrick Hwu, Francesco M. Marincola, Suzanne Topalian, Claudia A. Seipp, Jan H. Einhorn, Donald E. White, Seth M. Steinberg

Research output: Contribution to journalArticle

Abstract

Purpose: The combination of chemotherapy with immunotherapeutic agents such as interleukin-2 and interferon alfa-2b has been reported to provide improved treatment results in patients with metastatic melanoma, compared with the use of chemotherapy alone. We have performed a prospective randomized trial in patients with metastatic melanoma, comparing treatment with chemotherapy to treatment with chemoimmunotherapy. Patients and Methods: One hundred two patients with metastatic melanoma were prospectively randomized to receive chemotherapy composed of tamoxifen, cisplatin, and dacarbazine or this same chemotherapy followed by interferon alfa-2b and interleukin-2. Objective responses, survival, and toxicity in the two groups were evaluated at a median potential follow-up of 42 months. Results: In 52 patients randomized to receive chemotherapy, there were 14 objective responses (27%), including four complete responses. In 50 patients randomized to receive chemoimmunotherapy, there were 22 objective responses (44%) (P2 = .071), including three complete responses. In both treatment groups, the duration of partial responses was often short, and there was a trend toward a survival advantage for patients receiving chemotherapy alone (P2 = .052; median survival of 15.8 months compared with 10.7 months). Treatment-related taxicities were greater in patients receiving chemoimmunotherapy. Conclusion: With the treatment regimens used in this study, the addition of immunotherapy to combination chemotherapy increased toxicity but did not increase survival. The use of combination chemoimmunotherapy regimens is not recommended in the absence of well-designed, prospective, randomized protocols showing the benefit of this treatment strategy.

Original languageEnglish (US)
Pages (from-to)968-975
Number of pages8
JournalJournal of Clinical Oncology
Volume17
Issue number3
StatePublished - Mar 1999
Externally publishedYes

Fingerprint

interferon alfa-2b
Dacarbazine
Tamoxifen
Cisplatin
Interleukin-2
Melanoma
Drug Therapy
Survival
Therapeutics
Combination Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. / Rosenberg, Steven A.; Yang, James C.; Schwartzentruber, Douglas J.; Hwu, Patrick; Marincola, Francesco M.; Topalian, Suzanne; Seipp, Claudia A.; Einhorn, Jan H.; White, Donald E.; Steinberg, Seth M.

In: Journal of Clinical Oncology, Vol. 17, No. 3, 03.1999, p. 968-975.

Research output: Contribution to journalArticle

Rosenberg, Steven A. ; Yang, James C. ; Schwartzentruber, Douglas J. ; Hwu, Patrick ; Marincola, Francesco M. ; Topalian, Suzanne ; Seipp, Claudia A. ; Einhorn, Jan H. ; White, Donald E. ; Steinberg, Seth M. / Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 3. pp. 968-975.
@article{52ecbc481a3c474a8e7c0bda9fba8ff1,
title = "Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b",
abstract = "Purpose: The combination of chemotherapy with immunotherapeutic agents such as interleukin-2 and interferon alfa-2b has been reported to provide improved treatment results in patients with metastatic melanoma, compared with the use of chemotherapy alone. We have performed a prospective randomized trial in patients with metastatic melanoma, comparing treatment with chemotherapy to treatment with chemoimmunotherapy. Patients and Methods: One hundred two patients with metastatic melanoma were prospectively randomized to receive chemotherapy composed of tamoxifen, cisplatin, and dacarbazine or this same chemotherapy followed by interferon alfa-2b and interleukin-2. Objective responses, survival, and toxicity in the two groups were evaluated at a median potential follow-up of 42 months. Results: In 52 patients randomized to receive chemotherapy, there were 14 objective responses (27{\%}), including four complete responses. In 50 patients randomized to receive chemoimmunotherapy, there were 22 objective responses (44{\%}) (P2 = .071), including three complete responses. In both treatment groups, the duration of partial responses was often short, and there was a trend toward a survival advantage for patients receiving chemotherapy alone (P2 = .052; median survival of 15.8 months compared with 10.7 months). Treatment-related taxicities were greater in patients receiving chemoimmunotherapy. Conclusion: With the treatment regimens used in this study, the addition of immunotherapy to combination chemotherapy increased toxicity but did not increase survival. The use of combination chemoimmunotherapy regimens is not recommended in the absence of well-designed, prospective, randomized protocols showing the benefit of this treatment strategy.",
author = "Rosenberg, {Steven A.} and Yang, {James C.} and Schwartzentruber, {Douglas J.} and Patrick Hwu and Marincola, {Francesco M.} and Suzanne Topalian and Seipp, {Claudia A.} and Einhorn, {Jan H.} and White, {Donald E.} and Steinberg, {Seth M.}",
year = "1999",
month = "3",
language = "English (US)",
volume = "17",
pages = "968--975",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

AU - Rosenberg, Steven A.

AU - Yang, James C.

AU - Schwartzentruber, Douglas J.

AU - Hwu, Patrick

AU - Marincola, Francesco M.

AU - Topalian, Suzanne

AU - Seipp, Claudia A.

AU - Einhorn, Jan H.

AU - White, Donald E.

AU - Steinberg, Seth M.

PY - 1999/3

Y1 - 1999/3

N2 - Purpose: The combination of chemotherapy with immunotherapeutic agents such as interleukin-2 and interferon alfa-2b has been reported to provide improved treatment results in patients with metastatic melanoma, compared with the use of chemotherapy alone. We have performed a prospective randomized trial in patients with metastatic melanoma, comparing treatment with chemotherapy to treatment with chemoimmunotherapy. Patients and Methods: One hundred two patients with metastatic melanoma were prospectively randomized to receive chemotherapy composed of tamoxifen, cisplatin, and dacarbazine or this same chemotherapy followed by interferon alfa-2b and interleukin-2. Objective responses, survival, and toxicity in the two groups were evaluated at a median potential follow-up of 42 months. Results: In 52 patients randomized to receive chemotherapy, there were 14 objective responses (27%), including four complete responses. In 50 patients randomized to receive chemoimmunotherapy, there were 22 objective responses (44%) (P2 = .071), including three complete responses. In both treatment groups, the duration of partial responses was often short, and there was a trend toward a survival advantage for patients receiving chemotherapy alone (P2 = .052; median survival of 15.8 months compared with 10.7 months). Treatment-related taxicities were greater in patients receiving chemoimmunotherapy. Conclusion: With the treatment regimens used in this study, the addition of immunotherapy to combination chemotherapy increased toxicity but did not increase survival. The use of combination chemoimmunotherapy regimens is not recommended in the absence of well-designed, prospective, randomized protocols showing the benefit of this treatment strategy.

AB - Purpose: The combination of chemotherapy with immunotherapeutic agents such as interleukin-2 and interferon alfa-2b has been reported to provide improved treatment results in patients with metastatic melanoma, compared with the use of chemotherapy alone. We have performed a prospective randomized trial in patients with metastatic melanoma, comparing treatment with chemotherapy to treatment with chemoimmunotherapy. Patients and Methods: One hundred two patients with metastatic melanoma were prospectively randomized to receive chemotherapy composed of tamoxifen, cisplatin, and dacarbazine or this same chemotherapy followed by interferon alfa-2b and interleukin-2. Objective responses, survival, and toxicity in the two groups were evaluated at a median potential follow-up of 42 months. Results: In 52 patients randomized to receive chemotherapy, there were 14 objective responses (27%), including four complete responses. In 50 patients randomized to receive chemoimmunotherapy, there were 22 objective responses (44%) (P2 = .071), including three complete responses. In both treatment groups, the duration of partial responses was often short, and there was a trend toward a survival advantage for patients receiving chemotherapy alone (P2 = .052; median survival of 15.8 months compared with 10.7 months). Treatment-related taxicities were greater in patients receiving chemoimmunotherapy. Conclusion: With the treatment regimens used in this study, the addition of immunotherapy to combination chemotherapy increased toxicity but did not increase survival. The use of combination chemoimmunotherapy regimens is not recommended in the absence of well-designed, prospective, randomized protocols showing the benefit of this treatment strategy.

UR - http://www.scopus.com/inward/record.url?scp=0032976897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032976897&partnerID=8YFLogxK

M3 - Article

C2 - 10071291

AN - SCOPUS:0032976897

VL - 17

SP - 968

EP - 975

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -